Programme

Thursday, 16 May 2019 (OPTIONAL)

12.00 - 19.00  Live surgery programme Molinette Hospital

Friday, 17 May 2019

08.00 - 08.15  Introduction to the meeting and its format
J. Palou, Barcelona (ES)
A. Stenzl, Tübingen (DE)

08.15 - 09.00  Muscle Invasive Bladder Cancer (MIBC)
Chairs: A. Necchi, Milan (IT)
A. Stenzl, Tübingen (DE)

08.15 - 08.30  How much TURBT in patients with presumably MIBC prior to definitive therapy
F. Witjes, Nijmegen (NL)

08.30 - 08.45  Bladder sparing approaches in MIBC: Towards a standard of care?
A. Bossi, Villejuif (FR)

08.45 - 09.00  Neoadjuvant or adjuvant chemotherapy in localised MIBC?
T. Powles, London (GB)

09.00 - 12.30  Case discussion 1 (Interactive voting session)
Faculty group 1: Open or robotic radical cystectomy? (Duel)
Speakers: P. Gontero, Turin (IT)
J. Palou, Barcelona (ES)

Faculty group 2: Is there an oncological benefit of an extended lymphadenectomy in bladder cancer?
Speakers: M. Babjuk, Prague (CZ)
F. Witjes, Nijmegen (NL)
Faculty group 3: **Choice of urinary diversion: An interdisciplinary perspective**

Speakers: A. Stenzl, Tübingen (DE)
M. Ribal, Barcelona (ES)

09.00 - 10.00
- Faculty group 1
- Faculty group 2
- Faculty group 3
  
  Sala 500 (Plenary room)
  Sala Madrid
  Sala Londra

**10.00 - 10.30**
**Coffee break**

10.30 - 11.30
- Faculty group 2
- Faculty group 3
- Faculty group 1
  
  Sala 500 (Plenary room)
  Sala Madrid
  Sala Londra

11.30 - 12.30
- Faculty group 3
- Faculty group 1
- Faculty group 2
  
  Sala 500 (Plenary room)
  Sala Madrid
  Sala Londra

**12.30 - 13.30**
**Lunch**

**13.30 - 14.00**
**Non-Muscle Invasive Bladder Cancer (NMIBC)**

Chairs: M. Babjuk, Prague (CZ)
A. Stenzl, Tübingen (DE)

13.30 - 13.45
The best TURBT in 2019: From optimal visualisation to optimal resection
A. Breda, Barcelona (ES)

13.45 - 14.00
Non-immunological intravesical treatment: What’s new?
P. Black, Vancouver (CA)

**14.00 - 17.30**
**Case discussion 2 (Interactive voting session)**

Faculty group 1: **Sophisticated tumour visualisation: Clinical and prognostic implications**

Speakers: M. Babjuk, Prague (CZ)
B. Malavaud, Toulouse (FR)

Faculty group 2: **Standard and new techniques of TURBT**

Speakers: A. Breda, Barcelona (ES)
J. Dominguez Escrig, Valencia (ES)

Faculty group 3: **Adjuvant treatment in NMIBC: Where are we?**

Speakers: P. Black, Vancouver (CA)
F. Soria, Turin (IT)

14.00 – 15.00
- Faculty group 1
- Faculty group 2
- Faculty group 3
  
  Sala 500 (Plenary room)
  Sala Madrid
  Sala Londra
Saturday, 18 May 2019

**08.00 - 09.00** **Pathological assessment and molecular staging**
Chairs: P. Gontero, Turin (IT)  
A. Necchi, Milan (IT)

**08.00 - 08.15** Molecular staging: How far from routine pathological assessment?  
E. Comperat, Paris (FR)

**08.15 - 08.30** Variant (aberrant) pathologies: From diagnosis to optimal management  
P. Black, Vancouver (CA)

**08.30 - 08.45** Genomic approach in BCa: From bench to bedside  
F. Liedberg, Malmö (SE)

**08.45 - 09.00** Discussion  
Chairs: P. Gontero, Turin (IT)  
A. Necchi, Milan (IT)

Panellists:  
E. Comperat, Paris (FR)  
P. Black, Vancouver (CA)  
F. Liedberg, Malmö (SE)

**09.00 - 12.30** **Case discussion 3 (Interactive voting session)**

Faculty group 1: **Non-urothelial and aberrant urothelial histology: Its prognosis and impact on treatment decisions**
Speakers:  
S. Shariat, Vienna (AT)  
P. Black, Vancouver (CA)

Faculty group 2: **Radical cystectomy: How to handle the complications?**
Speakers:  
J. Palou, Barcelona (ES)  
P. Gontero, Turin (IT)

Faculty group 3: **Management and follow-up of low and intermediate risk tumours**
Speakers:  
F. Liedberg, Malmö (SE)  
F. Soria, Turin (IT)
09.00 - 10.00  Faculty group 1 Sala 500(Plenary room)
Faculty group 2 Sala Madrid
Faculty group 3 Sala Londra

10.00 - 10.30  Coffee break

10.30 - 11.30  Faculty group 2 Sala 500(Plenary room)
Faculty group 3 Sala Madrid
Faculty group 1 Sala Londra

11.30 - 12.30  Faculty group 3 Sala 500(Plenary room)
Faculty group 1 Sala Madrid
Faculty group 2 Sala Londra

12.30 – 13.30  Lunch

13.30 - 14.00  What’s new in diagnosing and staging of urothelial cancer?
Chairs: P. Gontero, Turin (IT)
A. Stenzl, Tübingen (DE)

13.30 - 13.45  Novel urinary markers: Ready to overcome urine cytology and cystoscopy?
L-M. Krabbe, Münster (DE)

13.45 – 14.00  Multiparametric magnetic resonance imaging and staging in bladder cancer
R. Faletti, Turin (IT)

14.00 - 14.45  Update on medical therapies
Chairs: J. Palou, Barcelona (ES)
A. Stenzl, Tübingen (DE)

14.00 - 14.15  Sequencing of new therapeutic options in metastatic urothelial cancer
A. Necchi, Milan (IT)

14.15 - 14.30  UTUC: biological and therapeutic rationale
J. Baard, Amsterdam (NL)

14.30 - 14.45  Emerging role of immunotherapy in neoadjuvant and adjuvant setting
S. Shariat, Vienna (AT)

14.45 - 15.30  Panel case discussion: Critical decision making in NMIBC
Chair: P. Gontero, Turin (IT)
Case presenter: F. Soria, Turin (IT)
Panellists: M. Babjuk, Prague (CZ)
F. Liedberg, Malmö (SE)
A. Necchi, Milan (IT)
J. Palou, Barcelona (ES)

15.30 - 15.40  Close
J. Palou, Barcelona (ES)
A. Stenzl, Tübingen (DE)